Literature DB >> 19509

Clinical pharmacokinetics of lorazepam. IV. Long-term oral administration.

D J Greenblatt, J A Knowles, W H Comer, R I Shader, J S Harmatz, H W Ruelius.   

Abstract

Fifteen healthy male volunteers received long-term daily treatment with oral lorazepam at doses as high as 10 mg per day for a period of 26 weeks. Steady-state plasma concentrations of lorazepam and its glucuronide metabolite were measured in all subjects at least every two weeks. At daily doses of 6 mg per day, the mean steady-state lorazepam level was 88 ng/ml and that of lorazepam glucuronide was 170 ng/ml. Mean levels among seven subjects who received 10 mg per day were 164 and 266 ng/ml, respectively. Lorazepam concentrations fluctuated from week to week despite constant dosage, but there was no evidence of systematic variation. Mean steady-state lorazepam levels were highly correlated with daily dose in mg/kg, but were not related to age. Lorazepam was not detected in any plasma samples drawn one week after discontinuation of treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 19509     DOI: 10.1002/j.1552-4604.1977.tb05642.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  3 in total

1.  Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.

Authors:  D J Greenblatt; M D Allen; D S MacLaughlin; D H Huffman; J S Harmatz; R I Shader
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

Review 2.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

Review 3.  Time-dependence in benzodiazepine pharmacokinetics. Mechanisms and clinical significance.

Authors:  T W Guentert
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.